Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report
Abstract The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable. However, here we present two cases of life‐threatening aplastic anemia (AA) upon treatment with the BTKi acalab...
| 發表在: | eJHaem |
|---|---|
| Main Authors: | , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
Wiley
2024-08-01
|
| 主題: | |
| 在線閱讀: | https://doi.org/10.1002/jha2.929 |